Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide for Lumbar Disc Degeneration
NCT03708926Phase 2Withdrawn
- Sponsor
- Johns Hopkins University
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lumbar degenerative disc syndrome (LDDS) comparing Abaloparatide with Placebo (2 arms). Primary endpoint: Composite score aggregated from the Oswestry Disability Index (ODI) and Pfirrmann grading system at 6 months. Planned start Mar 2021; status: withdrawn.
02
Drugs
abaloparatide
03
Conditions
lumbar degenerative disc syndrome (LDDS)
Beyond the preview
Go deeper on NCT03708926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708926.